针对阿尔茨海默氏症病理学的领先血液测试的对比比较
medRxiv : the preprint server for health sciences
|July 1, 2024
概括
新的阿尔茨海默病 (AD) 血液测试显示有希望. 血p-tau217在识别粉样蛋白病理和其他AD结果方面表现出最强的准确性,改善了诊断潜力.
科学领域:
- 神经学 神经学
- 生物标志物发现发现
- 诊断发展 诊断发展
背景情况:
- 阿尔茨海默病 (AD) 诊断依赖于昂贵的方法.
- 准确的AD诊断对于获得治疗至关重要.
- 血液测试为更容易获得的AD诊断提供了潜在的机会.
研究的目的:
- 为了比较领先的商业阿尔茨海默病血液测试的诊断准确度.
- 为了评估血液测试的表现与已建立的AD结局措施相比.
- 为了确定最佳的血生物标志物用于AD检测.
主要方法:
- 分析了来自阿尔茨海默病神经成像计划的血样本.
- 使用了多种商业性阿尔茨海默病血液测试.
- 测试测量了粉样蛋白病理,病理,皮质厚度和痴呆症的严重程度.
主要成果:
- 血p-tau217显示了与所有AD结局的最强相关性.
- 单个和组合的血生物标志物被评估为分类准确性.
- 评估了血生物标志物和连续结果之间的相关性.
结论:
- 血p-tau217是阿尔茨海默病的高度准确的生物标志物.
- 这项研究确定了用于可靠的AD诊断的特定血液测试和分析物.
- 这些发现支持基于血液的阿尔茨海默病生物标志物的临床实用性.
相关概念视频
01:26Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
01:22Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178